DNA
Price
$9.05
Change
-$0.04 (-0.44%)
Updated
Jul 13 closing price
Capitalization
591.19M
23 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$3.30
Change
-$0.26 (-7.30%)
Updated
Jul 13 closing price
Capitalization
1.75B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNA vs RXRX

DNA vs RXRX Comparison Chart in %
View a ticker or compare two or three
VS
DNA vs. RXRX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a Hold and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (DNA: $9.05 vs. RXRX: $3.30)
Brand notoriety: DNA and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNA: 53% vs. RXRX: 94%
Market capitalization -- DNA: $591.19M vs. RXRX: $1.75B
DNA [@Biotechnology] is valued at $591.19M. RXRX’s [@Biotechnology] market capitalization is $1.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNA’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • DNA’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, DNA is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNA’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 3 bullish TA indicator(s).

  • DNA’s TA Score: 5 bullish, 5 bearish.
  • RXRX’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, DNA is a better buy in the short-term than RXRX.

Price Growth

DNA (@Biotechnology) experienced а -10.48% price change this week, while RXRX (@Biotechnology) price change was -16.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.

Reported Earning Dates

DNA is expected to report earnings on Aug 06, 2026.

RXRX is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Biotechnology (-3.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($1.75B) has a higher market cap than DNA($591M). DNA YTD gains are higher at: 8.905 vs. RXRX (-19.315). DNA has higher annual earnings (EBITDA): -251.5M vs. RXRX (-478.66M). RXRX has more cash in the bank: 654M vs. DNA (373M). RXRX has less debt than DNA: RXRX (72.4M) vs DNA (411M). DNA has higher revenues than RXRX: DNA (151M) vs RXRX (65.7M).
DNARXRXDNA / RXRX
Capitalization591M1.75B34%
EBITDA-251.5M-478.66M53%
Gain YTD8.905-19.315-46%
P/E RatioN/AN/A-
Revenue151M65.7M230%
Total Cash373M654M57%
Total Debt411M72.4M568%
TECHNICAL ANALYSIS
Technical Analysis
DNARXRX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 18 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
DNA
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MBSF25.720.02
+0.08%
Regan Floating Rate MBS ETF
RFFC75.18N/A
N/A
ALPS Active Equity Opportunity ETF
WMSB24.99-0.06
-0.22%
Weitz Multisector Bond ETF
NVII24.35-0.70
-2.79%
REX NVDA Growth & Income ETF
FLKR55.21-4.83
-8.04%
Franklin FTSE South Korea ETF